Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- SEMINAR
November 5, 2007
- Lonasen, Clexane, Amage Recommended for Approval
November 5, 2007
- Korosho Found to Have Identifying Information on 118 Hepatitis C Patients
November 5, 2007
- BUSINESS NEWS IN BRIEF
November 5, 2007
- Gastric Cancer GL Stress Use of TS-1 for Inoperable Patients
November 5, 2007
- Kirin HD-Kyowa Hakko Deal Beneficial for Kirin HD, Neutral for Kyowa Hakko's Shareholders: DIR Report
November 5, 2007
- Defensive Factor Enhancing Agents Not Recommended after Endoscopic Therapy
November 5, 2007
- Mr Sekiguchi Explains PhRMA's Stance Regarding NHI Pricing
November 5, 2007
- MEDICAL DEVICE NEWS IN BRIEF
November 5, 2007
- Novartis to Cut 1,260 Jobs in the US
November 5, 2007
- R&D NEWS IN BRIEF
November 5, 2007
- GSK to Save ￡700 Mil. Each Year from 2010
November 5, 2007
- GNI's 3 Genes/Proteins Patented in China
November 5, 2007
- Hub Customization System Reduces Transportation Cost: Eli Lilly
November 5, 2007
- Lu AA24530 Enters PII in Europe: Takeda
November 5, 2007
- Create Joint Ventures in India: Mr Kurogi
November 5, 2007
- TOPICS／Janssen Holds "Dodge Ball" Event to Recruit New Graduates
November 5, 2007
- NEW PRODUCTS／Travatanz Ophthalmic Solution 0.004%: Alcon Japan
November 5, 2007
- REGULATORY NEWS IN BRIEF
November 5, 2007
- EPS Ties Up with CCPIE to Help Japanese Drug Firms Enter Chinese Market
November 5, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…